SR One, the corporate venture capital arm of GlaxoSmithKline, has led a $30m funding round for London-based biotechnology company Pulmocide.
Company has raised €20m so far over two funding rounds
HV Holtzbrinck and Lakestar also participate in the round for the dental technology startup
IK VIII held a final close in November 2016 with €1.85bn and was 87% deployed as of December 2019
With the GP's support, Bomi intends to pursue an intensive buy-and-build strategy